Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Slightly Bullish +25

Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD) Following Positive HIV Trial Results

AI-generated analysis

πŸ“ˆ Cantor Fitzgerald restated an Overweight rating on Gilead Sciences (GILD) with a $155 price target following positive HIV trial results.

πŸ’Š Phase 3 studies ISLEND-1 and ISLEND-2 showed solid top-line results for weekly islatravir/lenacapavir for HIV medication in collaboration with Merck.

⚠️ Gilead reported negative findings from the EVOKE-03 study comparing Trodelvy plus Keytruda versus Keytruda monotherapy in non-small cell lung cancer patients.

πŸ”¬ RBC Capital reaffirmed a $122 Sector Perform rating, noting Gilead's progress in in vivo CAR-T treatment technology.

βš–οΈ Analysts identify in vivo CAR-T as a potential risk to a sector representing 10-15% of Gilead's potential revenue.

πŸ“Š Gilead develops treatments for HIV-1, hepatitis B/C, primary biliary cholangitis, and serious invasive fungal infections.

πŸš€ The company also offers T-cell and CAR T-cell therapies for adult patients alongside COVID-19 treatments.

πŸ“° The article includes promotional links to unrelated stock movers like Sandisk (SNDK) and BlackBerry (BB).

Bullish Signals
  • Cantor Fitzgerald maintains an Overweight rating on Gilead Sciences with a $155 price target, signaling continued institutional confidence.
  • Positive Phase 3 clinical trial results for islatravir/lenacapavir in HIV treatment demonstrate strong pipeline efficacy and potential commercial value.
Risk Factors
  • Negative findings from the EVOKE-03 study regarding Trodelvy plus Keytruda in non-small cell lung cancer present a setback for that specific therapeutic combination.
  • RBC Capital identifies in vivo CAR-T technology as a potential risk to a sector estimated at 10-15% of Gilead's potential revenue.
Full Analysis
Cantor Fitzgerald has reiterated an Overweight rating on Gilead Sciences (GILD) with a $155 price target, citing positive Phase 3 clinical trial results for the HIV medication islatravir/lenacapavir. The studies, known as ISLEND-1 and ISLEND-2, demonstrated solid top-line efficacy when administered weekly in collaboration with Merck. Conversely, Gilead reported negative findings from the EVOKE-03 study, which compared Trodelvy combined with Keytruda against Keytruda monotherapy for first-line PD-L1 non-small cell lung cancer. This mixed clinical data presents a nuanced picture of the company's pipeline performance across different therapeutic areas. RBC Capital maintained its Sector Perform rating on Gilead Sciences at $122, highlighting the firm's progress in developing in vivo CAR-T technology. Analysts note that this emerging field represents a potential risk to a sector estimated to account for 10-15% of Gilead's potential revenue, though the company is building differentiating features. The article concludes with promotional content from Insider Monkey suggesting investors look elsewhere for AI stocks, while listing unrelated market movers like Sandisk and BlackBerry. The core financial news focuses on Gilead's specific clinical outcomes and analyst price targets.